BioSpace News Archive

This week, the American Academy of HIV Medicine launched a new online resource, www.hivlaa.org, to expand the knowledge base for long-acting antiretroviral agents used for the treatment and prevention of HIV.

Oncotelic Therapeutics, Inc. (“Oncotelic”, “We” or the “Company”) (OTCQB:OTLC) today announced financial results for the three months ended June 30, 2022 (“Q2 2022”) as compared to the three months ended June 30, 2021 (“Q2 2021”).

EpiVario, Inc., an emerging biotech company developing novel therapeutics for memory-related psychiatric disorders, today highlighted preclinical research findings that could lead to a treatment approach for PTSD.

Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (“Alpha Cognition,” or the “Company”), today announced positive results from a bioequivalence study with ALPHA-1062, a proprietary, delayed release oral tablet formulation in development for the treatment of mild to moderate Alzheimer’s Disease (AD).

Pi-Cardia Ltd., a global leader in the development of non-implant, catheter-based solutions for treating heart valves, announced a successful First-In-Human treatment of the mitral valve with the ShortCut™ Mitral device in Europe.

Lucid Hearing, LLC, a market leader and global provider of advanced hearing technology and audio solutions, commends the Food and Drug Administration (FDA) for its efforts to give Americans expanded access to hearing solutions.

Thermedical®, a developer of thermal-ablation systems to treat ventricular arrhythmias, announced today that the U.S. Food & Drug Administration (FDA) has approved an open-label, single-arm interventional clinical trial to evaluate the safety and efficacy of the Thermedical® SERF Ablation System with the Durablate® Catheter in people with ventricular tachycardia (VT) resistant to conventional treatment.

DisperSol Technologies, LLC, a specialty pharmaceutical company, today announced the appointment of Tim Scott as president and chief executive officer (CEO) of the company.

The growth of the gastrointestinal diagnostics market is attributed to the increasing incidence of gastrointestinal disorders such as gastric infections, IBD, GERD, GI bleeding, and others.

According to Report, the global high-performance liquid chromatography market was surpassed at USD 4.31 billion in 2021 and is expected to hit around USD 7.26 billion by 2030, growing at a CAGR of 5.96% from 2022 to 2030